EUVIMED · CrossrefZeitschrift
Leukemia Supplements
ISSN 2044-5210 · Springer Science and Business Media LLC
Neueste Artikel
Viral infections in patients with hematological malignancies
Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM): introduction by the co-chairpersons of the COSTEM Congress
Optimal induction and post-remission therapy for acute myeloid leukemia
Treating older patients with AML
Novel strategies in treatment of acute promyelocytic leukemia
Antibiotic therapy in hematological neutropenic patients: what is the news?
Fungal infections: diagnostic problems and choice of therapy
The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1
Prognostic factors in CLL
Chronic lymphocytic leukemia: treatment of relapse
Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors
Molecular basis of myelodysplastic syndromes
Initial treatment for patients with chronic myeloid leukemia
Second-generation TKIs: which and when?
Biology of CML stem cells: the basis for clinical heterogeneity?
Stem cell persistence in chronic myeloid leukemia
Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors
Where are we going with CML research?
Normal and leukemic stem cells
Faculty Presentations at The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Change in prognostic factors
Minimal residual disease
Modern therapy of young and adult Ph-ALL
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
Advances in unrelated cord blood transplants in malignancies
Prognostic markers in AML: focus on CBFL
Advances in current treatment for patients with newly diagnosed multiple myeloma
Challenges in multiple myeloma diagnosis and treatment
Stem cell transplantation for multiple myeloma: current and future status
EUVIMED